<SEC-DOCUMENT>0001144204-17-034242.txt : 20170627
<SEC-HEADER>0001144204-17-034242.hdr.sgml : 20170627
<ACCEPTANCE-DATETIME>20170627094821
ACCESSION NUMBER:		0001144204-17-034242
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170623
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170627
DATE AS OF CHANGE:		20170627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		17931307

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v469701_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
June 23, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">BIOANALYTICAL SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registrant&rsquo;s telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2017, Bioanalytical
Systems, Inc. (the &ldquo;Company&rdquo;) entered into a Credit Agreement (the &ldquo;Credit Agreement&rdquo;) with First Internet
Bank of Indiana (the &ldquo;Lender&rdquo;). The Credit Agreement provides the Company with (i) a term loan (the &ldquo;Term Loan&rdquo;)
in the amount of $4,500,000, which was used to satisfy the Company&rsquo;s outstanding indebtedness with The Huntington Bank, and
(ii) a revolving line of credit of up to $2,000,000 (the &ldquo;Facility&rdquo;), which the Company may borrow from time to time,
subject to the terms of the Credit Agreement. The Term Loan and the Facility mature June 23, 2022 and June 23, 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amounts outstanding
under the Term Loan bear interest at a fixed per annum rate of 3.99%, while interest accrues on the principal balance of the Facility
at a floating per annum rate equal to the Prime Rate (generally defined as the highest rate identified as the &ldquo;Prime Rate&rdquo;
in The Wall Street Journal &ldquo;Money Rates&rdquo; column on the date the interest rate is to be determined, or if that date
is not a publication date, on the publication date immediately preceding) less Twenty-five (25) Basis Points (0.25%). The Term
Loan requires monthly principal payments of $25,000 plus interest. The Company must also pay accrued and unpaid interest on the
outstanding balance under the Facility on a monthly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s obligations under the Credit Agreement are guaranteed by BAS Evansville, Inc., the Company&rsquo;s wholly owned
subsidiary</FONT> (&ldquo;<FONT STYLE="font-size: 10pt">BASEV&rdquo;). The Company&rsquo;s obligations under the Credit Agreement
and BASEV&rsquo;s obligations under the Guaranty are secured by first priority security interests in substantially all of the assets
of the Company and BASEV, respectively, as well as mortgages on the Company&rsquo;s and BASEV&rsquo;s facilities in West Lafayette,
Indiana and Evansville, Indiana, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Credit Agreement
contains various restrictive covenants, including restrictions on the Company&rsquo;s ability to dispose of assets, make acquisitions
or investments, incur debt or liens, make distributions to shareholders or repurchase outstanding stock, enter into related party
transactions and make capital expenditures, other than upon satisfaction of the conditions set forth in the Credit Agreement. The
Company is also required to comply with certain financial and non-financial covenants, including a minimum debt service coverage
ratio and a debt to equity ratio. Upon an event of default, which includes certain customary events such as, among other things,
a failure to make required payments when due, a failure to comply with covenants, certain bankruptcy and insolvency events, and
defaults under other material indebtedness, the Lender may cease advancing funds, increase the interest rate on outstanding balances,
accelerate amounts outstanding, terminate the agreement and foreclose on all collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing general
description of the Credit Agreement is qualified in its entirety by reference to the full text of the Credit Agreement, a copy
of which will be filed with the Company&rsquo;s Form 10-Q for the period ending June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.03 Creation of a Direct Financial
Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information provided
in response to Item 1.01 of this Report is incorporated by reference in response to this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press Release dated June 27, 2017.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">BIOANALYTICAL SYSTEMS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">Date: June 27, 2017</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 30%; border-bottom: Black 1pt solid">/s/ Jill C. Blumhoff</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Jill C. Blumhoff<BR>Chief Financial Officer, Vice President of Finance</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><U>Exhibit No.</U></TD><TD STYLE="text-align: justify"><U>Description</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press Release dated June 27, 2017.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v469701_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; text-align: left"><IMG SRC="basi_logo.jpg"></TD>
    <TD STYLE="width: 50%; text-align: right"><IMG SRC="news_release.jpg"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 55%; text-align: left"><B>FOR MORE INFORMATION:</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 43%; text-align: right"><B>Company Contact:</B></TD></TR>
<TR>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">Jill Blumhoff</TD></TR>
<TR>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">Chief Financial Officer &amp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">Vice President of Finance</TD></TR>
<TR>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">Phone: 765.497.8381</TD></TR>
<TR>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">jblumhoff@BASinc.com</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BASi Completes Refinancing of Senior
Secured Credit Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WEST LAFAYETTE, IN</B>, June 27, 2017 -- <B>Bioanalytical
Systems, Inc. (NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;)</B> today announced that it has successfully completed
the refinancing of its existing senior secured credit facility with a new senior secured credit facility, consisting of a $4.5
million term loan and a $2.0 million revolving credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Today marks a significant accomplishment
of one of the many objectives that we envisioned for BASi&rsquo;s ongoing success&rdquo;, stated Jill Blumhoff, Chief Financial
Officer and Vice President of Finance for BASi. &ldquo;This is a very exciting milestone for the Company, which meaningfully advances
our financial flexibility leaving us well positioned to operate our business for the long-term, and capitalize on opportunities
in the future. I want to thank our BASi employees and board members for their support in this accelerated effort, as well as our
customers, shareholders, and new lender.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The refinancing led by First Internet Bank
of Indiana extends the maturities of the Company&rsquo;s debt, with the revolving credit facility maturing in June 2019 and the senior
secured term loan maturing in June 2022. Payments on the term loan are based on a fifteen year amortization schedule. The Company
will use approximately $4.6 million of the loan proceeds to repay its obligations under its existing credit facility. The remaining
availability on the revolving credit facility of $1.9 million, if borrowed, will be used for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest rate for the $4.5 million
senior secured term loan will be at a fixed per annum rate equal to 3.99%.&nbsp; The interest rate for borrowings under the $2.0
million revolving credit facility will be at the Prime Rate less 0.25% per annum.&nbsp; The 2017 Senior Secured Credit Facilities
are subject to customary affirmative, negative and financial covenants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About First Internet Bank</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
First Internet Bank opened for business in 1999 as an industry pioneer in the branchless delivery of banking services. With assets
of $2.1 billion as of March 31, 2017, the Bank now provides consumer and small business deposit, consumer loan, residential mortgage,
and specialty finance services nationally. The Bank also offers commercial real estate loans, commercial and industrial loans and
treasury management services in select geographies. Additional information about the Bank, including its products and services,
is available at www.firstib.com. The Bank is a wholly owned subsidiary of First Internet Bancorp (NASDAQ: INBK).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Bioanalytical Systems, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BASi is a pharmaceutical development company
providing contract research services and monitoring instruments to the world&rsquo;s leading drug development companies and medical research
organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost
of taking a new drug to market. Visit www.basinc.com for more information about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>This release contains forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to our financial
condition, changes in the market and demand for our products and services, the development, marketing and sales of products and
services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in
the Company&rsquo;s filings with the Securities and Exchange Commission. BASi assumes no obligation to update any forward-looking statement.
Actual results may vary, and could differ materially, from those anticipated, estimated, projected or expected in these forward-looking
statements for a number of reasons, including, among others, the risk factors disclosed in the Company&rsquo;s most recent Annual Report,
as filed, with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>basi_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 basi_logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )8# 2(  A$! Q$!_\0
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MWO!<FM1^%V_L:&TE8WC^9]H)&!L3&,$>]8/C_P#Y'"[_ -V/_P! %=C\,_\
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M[\;6#7-S-,W[SF1RQ_U;>M=3;1R1?"1EE5E8V[L WH7)!_(BN0\"?\CGI_\
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9)[@ [VB4JIYXP"?3%%3T5TI65CD;N[G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>news_release.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 news_release.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J . # 2(  A$! Q$!_\0
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M?J+:3X@M9WRMO<$V[L>G..YZ8.TGVKI.4]<DU"RAN5MI;RW2X; 6)I5#'/3
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MG!'\FI@<NEI/>>$M4U1_FS?1L[$\Y ;/ZRBM"QG.N>--$4OD6\$(W>Z)O/\
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MP,,$D@$3#*(3W]J ,[Q1I'B2TT])M5OQ=VHD *QR,0I[$@@?3/O6AK\MM/\
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:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
